Auxly Cannabis Group Inc. (CBWTF) is a Toronto-based consumer packaged goods company operating in the Canadian cannabis market under brands such as Back Forty, Kolab Project, Foray, Dosecann, and Parcel. Its U.S.-listed shares trade on the OTCQB, and the company completed a 14:1 share consolidation in late July 2026 that reset its price and capital structure. The question investors are weighing is whether the stock can climb from its recent price to a $3.20 price target.
Analyst coverage of CBWTF is unusually thin: roughly two analysts currently publish price targets, so the "analyst consensus" is a limited sample that should be read with caution. The two targets identified range from about $2.83 to $3.53 in U.S.-dollar terms, which corresponds to a range of approximately C$4.00 to C$5.00. The arithmetic mean of these two figures is approximately $3.18, rounded here to a $3.20 central target.
Because only two estimates exist, the low-to-high spread of roughly $0.70 represents a meaningful divergence of opinion. The higher estimate implies confidence that profitability and international expansion continue to compound, while the lower estimate reflects a more conservative view of a small-cap, OTC-listed cannabis operator. No single analyst should be treated as decisive, and the mean is a reference point rather than a guarantee.
The stock has traded recently around $2.40 following the 14:1 consolidation, well above its adjusted 52-week low but below its adjusted 52-week high near $2.66. Reaching $3.20 would require an advance of about 33%, a substantial move for any small-cap equity and especially so for a lightly traded OTC cannabis name.
The path would likely depend on continued delivery of the trends already visible in results. For the second quarter ended June 30, 2026, the company reported net revenue of $45.8 million, up 18% year over year, and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) of $14.3 million, up 24%. Gross margin on finished cannabis inventory sold improved to 55% from 52% a year earlier, and net income was $7.7 million, or $0.08 per basic share.
On an adjusted basis, the 52-week range spans roughly $1.06 to $2.66. The recent price near $2.40 sits in the upper portion of that range but below the prior high, which may act as a resistance level on any advance toward $3.20. A decisive move beyond the $2.66 area would leave the stock without well-defined overhead supply, while the consolidation-adjusted low near $1.06 marks a distant support level.
Analyst price targets typically reflect a research horizon of about 12 months, though the exact timeframe is not always disclosed. Investors should watch quarterly revenue and adjusted EBITDA trends, gross-margin direction, any updates on international expansion with Imperial Brands, share-buyback activity, and changes to the two covering analysts' targets. Sector-level developments in Canadian cannabis regulation and excise policy also matter, as do broader moves in interest rates and risk appetite for small-cap equities.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover new opportunities, monitor existing positions, and identify changing trends more efficiently than manual screening allows. For those tracking a thin, volatile name like CBWTF, automated signal monitoring can help surface momentum shifts worth a closer look.
The $3.20 target for CBWTF is the mean of just two analyst price targets, which range from about $2.83 to $3.53. From a recent price near $2.40, reaching that level would require a gain of roughly 33%, a substantial move supported by record revenue, widening margins, a strengthening balance sheet, and buybacks, but challenged by thin coverage, cannabis-sector competition, and the volatility typical of a small OTC-listed operator. Because only two estimates exist, the average carries limited statistical weight, and investors should treat it as a reference point while monitoring quarterly results, international progress, and any analyst revisions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.